Abstract
Specialty pharmacy service (SPS) companies are filling a new niche in the expanding role of chronic disease management (DM). Thesecompanies distribute expensive biotechnology drugs to patients who have relatively uncommon but very expensive chronic diseases. Although there are considerable differences among the competitors, some of the SPS companies have evolved into organizations that have built data systems and processes rivaling those offered by dedicated DM companies. These data systems and processes will allow several of the companies to demonstrate improved medical outcomes.
Since the SPS companies can fashion contracts where they do not charge a separate fee for the DM portion of their services, this model is especially attractive to managed-care organizations (MCOs) [both preferred provider organizations and health maintenance organizations] and to third-party administrators that operate in self-insured or administrative services only environments. These companies can also reduce the administrative burden for MCOs and the ‘hassle factor’ for physicians and patients by performing delegated prior-authorization functions for the MCO.
Pharmaceutical companies have played a key part in advising and assisting the development of the unique role of SPS companies. Future challenges and opportunities for this sector include: integration of comorbid conditions; publication of outcome results; customization of educational material to individual patient needs; and accreditation. MCOs and investors will recognize the development of an integrated, proven DM, outcome-driven business model as a key differentiation factor in this niche industry.
Similar content being viewed by others
References
Disease Management Association of America. [online]. Available from: URL: http://www.dmma.org [Accessed 2001 Sep 11]
Chase H&Q. Healthcare services changing channels: the emergence of specialty pharmacy services for biotech drugs. Equity Research Industry Report. Chase H&Q, a division of Chase Securities Inc.
National Committee for Quality Assurance. Disease management accreditation/certification [online]. Available from: http://www.ncqa.org/Programs/Accreditation/Certification/dmmain.htm [Accessed 2001 Aug 29]
Pharmaceutical Research and Manufacturers of America. New medicines in development [online]. Available from: URL: http://www.phrma.org/searchcures/newmeds/biotech2000/bio_intro.phtml [Accessed 2001 Aug 29]
Centers for Disease Control and Prevention, National Center for Infectious Diseases, Division of Viral and Rickettsial Diseases, Hepatitis Branch. Hepatitis C fact sheet [online]. Available from: URL: www.cdc.gov/ncidod/diseases/hepatitis/c/index.htm. [Accessed 2001 Sep]
National Institutes of Health (NIH) Consensus Development Panel. Management of hepatitis C. NIH Consensus Statement 1997; 15(3): 1–41
Dulworth S, Patel S. The hepatitis C epidemic: looking at the tip of the iceberg. Minneapolis (MN): Milliman & Robertson, Inc, 2000
McHutchison JG, Gordon SC, Schiff ER, et al. Hepatitis Intervention Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485–92
US Dept of Human and Health Services. Morbidity and Mortality Weekly Report. Prevention and control of hepatitis C virus (HCV) and HCV related diseases. Atlanta (GA): US Dept of Human and Health Services, 1998
Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 2c Suppl 1: 625–55
Schering Corporation. Be In Charge [online]. Available from: URL: http://www.beincharge.com http://www.beincharge.com [Accessed 2001 Aug 29]
Teva Neuroscience. MSWatch [online]. Available from: URL: http://www.mswatch.comwww.mswatch.com [Accessed 2001 Aug 29]
Minden SI, Schiffer RB. Affective disorders in multiple sclerosis: review and recommendations for clinical research. Arch Neurol 1990; 47: 98–104
Sadovnick AD, Eisen K, Ebers GC, et al. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991; 41: 1193–6
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Morrow, T. Specialty Pharmacies. Dis-Manage-Health-Outcomes 9, 531–538 (2001). https://doi.org/10.2165/00115677-200109100-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00115677-200109100-00002